Novo Nordisk A/S (NVO)

Market Cap	191.02B -26.5%
Revenue (ttm)	50.34B +5.6%
Net Income	17.79B +4.8%
EPS	4.00 +5.0%
Shares Out	4.43B
PE Ratio	10.74
Forward PE	14.37
Dividend	$1.28 (2.96%)
Ex-Dividend Date	Aug 17, 2026

Volume	10,370,709
Open	43.50
Previous Close	43.19
Day's Range	42.78 - 43.54
52-Week Range	35.12 - 64.16
Beta	0.34
Analysts	Hold
Price Target	46.80 (+8.23%)
Earnings Date	Nov 4, 2026

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,505
• Stock Exchange: NYSE
• Ticker Symbol: NVO
• Website: https://www.novonordisk.com

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Analyst Summary

According to 14 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $46.8, which is an increase of 8.23% from the latest price.

Price Target

$46.8

(8.23% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 19, 2026

Data Sources Report a data error